Login / Signup

Synergistic effect of two human-like monoclonal antibodies confers protection against orthopoxvirus infection.

Hadas TamirTal Noy-PoratSharon MelamedLilach Cherry-MimranMoria Barlev-GrossRon AlcalayYfat Yahalom-RonenHagit AchdoutBoaz PolitiNoam ErezShay WeissRonit RosenfeldEyal EpsteinOhad MazorEfi MakdasiNir ParanTomer Israely
Published in: Nature communications (2024)
The eradication of smallpox was officially declared by the WHO in 1980, leading to discontinuation of the vaccination campaign against the virus. Consequently, immunity against smallpox and related orthopoxviruses like Monkeypox virus gradually declines, highlighting the need for efficient countermeasures not only for the prevention, but also for the treatment of already exposed individuals. We have recently developed human-like monoclonal antibodies (mAbs) from vaccinia virus-immunized non-human primates. Two mAbs, MV33 and EV42, targeting the two infectious forms of the virus, were selected for in vivo evaluation, based on their in vitro neutralization potency. A single dose of either MV33 or EV42 administered three days post-infection (dpi) to BALB/c female mice provides full protection against lethal ectromelia virus challenge. Importantly, a combination of both mAbs confers full protection even when provided five dpi. Whole-body bioimaging and viral load analysis reveal that combination of the two mAbs allows for faster and more efficient clearance of the virus from target organs compared to either MV33 or EV42 separately. The combined mAbs treatment further confers post-exposure protection against the currently circulating Monkeypox virus in Cast/EiJ female mice, highlighting their therapeutic potential against other orthopoxviruses.
Keyphrases
  • endothelial cells
  • gene expression
  • helicobacter pylori
  • drug delivery
  • genome wide
  • helicobacter pylori infection
  • skeletal muscle
  • smoking cessation
  • pluripotent stem cells
  • replacement therapy
  • drug induced